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In Ashkenazi Jewish (AJ) high risk families 3 mutations [2 in BRCA1 (c. 68_69del and
c.5266dup) and 1 in BRCA2 (c.5946del)] account for the majority of high risk breast
and ovarian cancer cases in that ethnic group. Few studies with limited number of
genotyped individuals have expanded the spectrum of mutations in both BRCA genes
beyond the 3 mutation panel. In this study, 279 high risk individual AJ were counseled at
CEMIC (Centro de Educación Médica e Investigaciones Clínicas), and were genotyped
first for the 3 recurrent mutation panel followed by Next Generation Sequencing (NGS) of
BRCA1 BRCA2 in 76 individuals who tested negative for the first genotyping step. Of 279
probands (259 women), 55 (50 women) harbored one of the 3 mutations (19.7%); Of 76
fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in
BRCA1, c.2728C>T - p.(Gln910∗); c.5407-?_(∗1_?)del and c.5445G>A - p.(Trp1815∗);
in BRCA2, c.5351dup - p.(Asn1784Lysfs∗3); c.7308del - p.(Asn2436Lysfs∗33) and
c.9026_9030del - p.(Tyr3009Serfs∗7). Of 61 mutation carriers the distribution was as
follows: 11 cancer free at the time of genotyping, 34 female breast cancer cases with age
range 28–72 years (41.6± 9.3), 3 male breast cancer cases with age range 59–75 years
(65 ± 7.3), 6 breast and ovarian cancer cases with age range 35–60 years (breast 40.4
± 5.2; ovary 47.8 ± 7.2) and 7 ovarian cancer cases with age range 41–77 years (60.6
± 13.3). This information proved highly useful for counseling, treatment, and prevention
for the patient and the family. In conclusion comprehensive BRCA1/2 testing in AJ high
risk breast ovarian cancer cases adds valuable clinically relevant information in a subset
of cases estimated up to 7% and is therefore recommended.
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INTRODUCTION
Inherited pathogenic mutations in BRCA1 (OMIM∗113705) or
BRCA2 (OMIM∗600185) substantially increase lifetime risk for
breast, ovarian and to a lesser extent other cancer types defining
individuals who carry BRCA1 or BRCA2 cancer predisposing
mutations is valuable for both cancer cases and unaffected family
members: targeted treatment in the form of PARP inhibitors is
available for mutation carrying patients (1, 2), and early detection
schemes and risk-reducing strategies are offered to asymptomatic
mutation carriers (3, 4).
Near 300 BRCA1 and BRCA2 pathogenic mutations in the
Argentine population have been reported by our group (5, 6)
routinely deposited in Leiden Open Variation Database 3.0 (7)
and Leiden Open Variation Database–Chapter for Argentina (8),
most previously described in other world populations with∼10%
of novel pathogenic variants.
The estimated frequency of pathogenic germline mutations in
BRCA1 and BRCA2 genes in the general population in several
outbred populations vary between 1:300 and 1:800, respectively
(4). However, in inbred populations, with AJ as one of the most
frequently studied examples, the spectrum of BRCAmutations is
limited with higher rates in the general population. In this ethnic
group 1/40 individuals is a carrier one of 3 recurrent mutations
in BRCA1 [185delAG: c.68_69del (rs386833395) and 5382insC:
c.5266dup (rs80357906)], and BRCA2 [6174delT: c.5946del
(rs80359550)]. Such high rates in the general population and
consecutive breast and ovarian cancer cases enabled effective use
of cancer genetics services for AJ women (9).
FIGURE 1 | Patients of Ashkenazi origin with personal and/or family history (279 probands) were tested for the panel AJ founder mutations; among affected patients
24.3% were detected with a mutation while this rate was 11.2% in the non-affected individuals. Sixty three patients without AJ mutation were subjected to the
comprehensive BRCA1/2 analysis and 6 were diagnosed with a pathogenic mutation (9.5% from the analyzed probands). On the other hand, 98 were healthy
individuals with family history of cancers related to BRCA1/2 and, among them. The non-Ashkenazi mutations were detected always in affected patients.
For high risk AJ individuals not carrying one of these 3
founder alleles, the probability for other pathogenic mutations
in BRCA1 or BRCA2 has rarely been reported (10–13). In the
current study we report on an extended analysis of BRCA1/2 by
comprehensive next generation sequencing and analysis of point
mutations and large rearrangements in Ashkenazi patients with
personal and/or family history of cancer qualifying for the panel
analysis and testing normal for the 3 founder mutations.
MATERIALS AND METHODS
Study Subjects
The study focused on Ashkenazi Jewish individuals recruited
from those referred for counseling and genotyping at CEMIC
(Centro de Educación Médica e Investigaciones Clínicas)
between 2009 and 2017. Eligibility criteria for patient selection
are based on the NCCN guidelines [National Comprehensive
Cancer Network. Genetic/Familial High-Risk Assessment: Breast
and Ovarian (Version 1.2018) https://www.nccn.org/ Accessed
March 30, 2018]. For individuals of AJ origin, with no
known familial mutation, were first tested for the 3 AJ
specific mutations (see below genotyping methodology). Then,
for high risk individuals of AJ who tested negative for the
three mutations BRCA comprehensive BRCA genetic testing
was carried out (see below genotyping platform). Study
eligibility after genetic counseling required signing an informed
consent as part of the routine procedures for genetic analysis
(including Ethics Committee approval) at CEMIC, which
also complies with the Traditional Pretest Counseling for
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Susceptibility Testing (purpose of testing) described in the
American Society of Clinical Oncology Policy Statement Update
(14).
BRCA1/2 Testing Platforms
Genomic DNA of the 279 blood samples was isolated by MagNA
Pure R© LC instrument with total DNA isolation kit I (Roche
Diagnostics). All samples were analyzed by Sanger sequencing of
PCR amplified fragments for the 3 founder Ashkenazi mutations
c.68_69del and c.5266dup in BRCA1 and c.5946del in BRCA2.
Analysis of comprehensive BRCA1/2 sequencing and
large rearrangements by Multiple Ligation-dependent Probe
Amplification assay (MLPA) for eligible individuals was
performed by Next Generation Sequencing (NGS) by using the
Ion AmpliSeqBRCA1/2 community panel, as it allows to amplify
the entire coding sequences of BRCA1 and BRCA2, including 20–
50 bases of adjacent intronic sequence of each exon. The assay is
designed to ensure at least 200X total coverage/base. Sequencing
of the amplified regions was performed with the next generation
platform Personal Genome Machine R© System, as previously
described (6). Rare coding sequences with low coverage were
analyzed by Sanger sequencing to ensure higher coverage rates.
The raw signal data and the sequence reads were processed
with Ion Torrent Suite software (Thermo Fisher Scientific) on
a Torrent server. After data analysis, single nucleotide variants,
insertions, deletions, and splice site alterations were registered,
and all variants detected were reported. Sanger sequencing was
used to confirm all clinically relevant variants detected (class 3,
4, and 5). Clinical significance was determined according to the
reference databases: ClinVar (15), LOVD3.0 (7), and UMD (16)
as of March 2018.
For missense mutations not reported or reported with
uncertain clinical significance (VUS), in silico programs were
used to predict the change in protein function using software
Align-GVGD (http://agvgd.iarc.fr/), SIFT (http://sift.bii.a-star.
edu.sg), and Mutations Taster (http://www.mutationtaster.org/).
Large rearrangements were measured by MLPA using SALSA
MLPA Probemix P002 and P045 provided by MRC-Holland, and
Coffalyser.net software was used for data analysis; we confirm




Overall, we include 279 patients (Figure 1) recruited among
2009–2017 as depicted in Table 1. Age range at counseling
and genotyping was 20–87 years; 181 (174 females) had cancer
diagnoses (mean age 48.3 ± 11.2 years) and 98 were healthy,
cancer free high risk individuals (mean age at genotyping 47.7
± 11.8). Of cancer cases the distribution was as follows: of 174
cancer affected women, breast, 145 (age range 28–74 years, mean
47.0 ± 9.6), breast and ovarian 7 (age range breast 35–64 years,
mean 44.3 ± 9.8; age range ovary 41–64 years, mean 49.2 ±
8.9), ovarian 19 (age range 18–78 years, mean 52.5 ± 16.6) and
one each with pancreas (68 years), endometrium (58 years) and
melanoma (26 years). For the 7 cancer affected men, 6 had breast





Age range Age mean ± SD
Healthy women 9 40–58 47.7 ± 5.3
Healthy men 2 47 & 76 61.5 ± 20.5
Breast cancer women 34 28–72 41.6 ± 9.3
Breast cancer men 3 59–75 65 ± 7.3
Ovary cancer 7 41–77 60.6 ± 13.3
Breast and ovary 6
Breast 35–46 40.4 ± 5.2
Ovary 41–60 47.8 ± 7.2
Total with a mutation 61 (27.6%)*
*AJ mutations 55/279 (19.7%); Non-AJ mutations 6/76 (7.9%).
cancer (age range 59–75 years; mean 65.5 ± 5.7) and 1 with
prostate cancer (61 years).
The 279 selected patients were first analyzed through the
AJ founder mutation and, among those who tested normal, 76
patients were analyzed by the BRCA1/2 comprehensive study;
among the 6 patients with a non AJ mutation detected all but 2
were of full AJ origin, one was mixed Ashkenazi non Ashkenazi
and the other mixed Ashkenazi and non-Jewish. The ages ranged
from 20 to 87 years old; 181 of them were affected with a mean
age of 48.3 ± 11.2 and 98 of them were healthy with a mean age
of 47.7± 11.8.Table 1 summarizes the age range andmean age±
SD for subjects with a mutation detected separated by diagnosis
and gender. As eligible patients we included men or women
selected by their AJ ethnicity, with two exceptions (Figure 2):
proband [B: BRCA1 c.5407-?_(∗1_?)del] was half Sephardi, and
proband [D: BRCA2: c.5351dup - p.(Asn1784Lysfs∗3)] was half
non-Jewish, although this side was not the side associated with
inheritance of the syndrome.
Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1
mutation (n = 44) or a BRCA2 mutation (n = 17). Of these
mutations all but 3 in BRCA1 and 3 in BRCA2 were one of the
predominant AJ mutations in both genes.
Table 1 summarizes age at genotyping and/or cancer
diagnosis and type and gender of all mutation carriers and the
specific unique non founder mutations.
Figure 1 summarizes the genotype analysis of 279 individuals
with the DNA sequenced for the panel of the 3 founder Ashkenazi
mutations and full sequence by NGS technique and MLPA.
Table 1 lists the patients with a mutation detected, to be
remarked women with diagnosis of breast cancer were the
youngest (range starts at 28 years), mean age non-statistically
different from women with diagnosis of both, breast and ovary
cancer.
In Tables 2, 3 are detailed the mutations detected in females
and males respectively.
Figure 2 depicts the pedigrees for the six families with
a non AJ founder mutation. Of the 6 mutations found,
BRCA2 c.7308del - p.(Asn2436Lysfs∗33) has not been previously
reported and is therefore novel while the other 5 have been
reported in non-Jewish populations.
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FIGURE 2 | Pedigrees of the families carrying mutations in BRCA1/2 other than the Ashkenazi founder mutations. Circles: women; squares: men; half blackened
symbols: individuals affected with cancer; white symbols: unaffected individuals; TN: triple negative breast cancer; slash diagonal line: deceased. The cancer and age
at diagnosis are indicated below each individual when available. An arrow indicates the proband. (A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1
c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2
c.9026_9030del - p.(Tyr3009Serfs*7).
Regarding the families with a non-Ashkenazi mutation,
the particular details of the family history of cancers
related to BRCA was strong for the 6 probands, as shown
in the pedigrees drawn in Figure 2. The description
of the mutations are in Table 4, as follows: BRCA1:
c.2728C>T - p.(Gln910∗), rs397509004, c.5407-?_(∗1_?)del,
c.5445G>A - p.(Trp1815∗), rs397509284 and BRCA2:
c.5351dup - p.(Asn1784Lysfs∗3), rs80359508, c.7308del -
p.(Asn2436Lysfs∗33), c.9026_9030del - p.(Tyr3009Serfs∗7),
rs80359741.
DISCUSSION
The likelihood that AJ high risk individuals who do not carry any
of the predominant AJ mutations in BRCA1 and BRCA2 would
harbor a unique BRCA1 or BRCA2mutation in the present study
was 7.9%. As the family D was self-reported as half-non AJ, the
resulting prevalence for BRCA1/2 non AJ mutation excluding
this family results to be 5 out of 76 cases (6.6%). This rate is
line with previous studies, although there are only a few that
have reported such a focused analysis (10–13). In those previous
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TABLE 2 | Analysis of mutations detected in female individuals.
Female patients mutation analysis n % n (tumor type, age range or age@diag) Healthy
Recurring Ashkenazi mutations
Total 259
Gene: Mutation 50 19.3 9
BRCA1: c.68_69del -p.(Glu23Valfs*17) 24 9.3 18, Br (30-72); 1 Br/Ov (46, 47); 2, Ov (59, 77) 3 (*)
BRCA1: c.5266dup -p.(Gln1756Profs*74) 15 5.8 8, Br (28-46); 4, Ov (41-72); 2, Br/Ov (35,41; 37,45) 1
BRCA2: c.5946del -p.(Ser1982Argfs*22) 11 4.2 4, Br (30-56); 1 Br & Fallopian tube (64); 1 Br/Ov (46) 5
Unique mutations (NGS)
Total 73
Gene: Mutation 5 6.8
BRCA1: c.2728C>T - p.(Gln910*) 1 Ov (55) 0
BRCA1: c.5407-?_(*1_?)del 1 Br (37) 0
BRCA1: c.5445G>A - p.(Trp1815*) 1 Br (47)
BRCA2: c.7308del - p.(Asn2436Lysfs*33) 1 Br (38,45,47,52) & Ov (60, 64) 0
BRCA2: c.9026_9030del -
p.(Tyr3009Serfs*7)
1 Br (35) 0
n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer; Ov, Ovarian Cancer.
(*) a patient was carrier of the mutation in the gene MSH2: c.1906G>C - p.(Ala636Pro), also of Ashkenazi origin (17).
TABLE 3 | Analysis of mutations detected in male individuals.
Male patients
mutation analysis
n (%) age@diag Healthy
Ashkenazi mutation
Total 20
A mutation found 5 25.0 2
BRCA1: c.68_69del
-p.(Glu23Valfs*17)











A mutation found 1 33.3
BRCA2: c.5351dup -
p.(Asn1784Lysfs*3)
1 Br (66) 0
n, number of probands; age@diag, age at diagnosis; Br, Breast Cancer.
studies the rates were 4-5% of fully genotyped AJ cases. The
rationale behind our two step sample analysis approach lies in the
fact that non-routine tests in the Argentinian health care system
requires approval by a specialized committee that tends to not
approve oncogenetic testing for unaffected individuals despite
having a significant family history of cancer.
A rather difficult task is to express the results of this study,
as not all the patients without an Ashkenazi mutation were
analyzed by NGS and MLPA. As a consequence, the percentages
of mutations cannot be straightforwardly interpreted, which
may constitute a limitation for expressing the current findings.
However, our results still remain valid, as even if all samples
normal for the Ashkenazi panel had been tested for the
comprehensive BRCA1/2 study and no othermutation would had
been detected, the percentage obtained would still have been 3.3%
(6 out of 181 affected patients).
The population targeted in this study was selected on the
basis of clinically having features of inherited cancer syndrome.
Overall, non AJmutations were detected in 6.8% of female cancer
cases; 4.1% in female breast cancer cases and 2.7% in ovarian
cancer (alone or with breast cancer). These rates are higher
than those previously reported for Ashkenazi population, likely
due to different criteria used for patient selection (10, 11). The
highest mutation rates were found in cases of ovarian cancer
including breast cancer diagnosed in the same patient, 50%, with
similar rates to what was previously published by our group in a
description of 940 patients (6).
Worth highlighting, 11 out of these 13 mutations were among
the Ashkenazi panel and two detected by full analysis. The two
probands found to carry a mutation in BRCA1/2 support the
application of precision medicine: patients benefit from being
considered for poly–(adenosine diphosphate–ribose) polymerase
(PARP) inhibitor therapy (1, 2), while their families still qualify
for prevention measures as the first goal in these genetic studies.
Family history of cancer in first degree relatives as a major
selection criterion for selecting cases to be genotyped carries
an inherent limitation, as gender specific cancer (e.g., ovarian
cancer) cannot be used in cases where the mutation arises on
the paternal side yet, the value of incorporating second or third
degree relatives on either parental side has its own merits.
Moreover there are cases where the family history is distinct
or the paternal from the maternal sides and both should be
taken into account and guide the genetic testing platform. A case
that exemplifies this point is the patient who co-harbored the
MSH2 c.1906G>C - p.(Ala636Pro) (17) and BRCA1 c.68_69del -
p.(Glu23Valfs∗17). These findings are of the utmost importance,
as surveillance of the unaffected proband will focus on both
Lynch and hereditary breast-ovary cancer syndromes, while
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TABLE 4 | Families with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure 2.




This is a rare mutation reported in ClinVar and we deposited in LOVD (Genomic Variant #0000206572). The
proband with age 71 at testing had ovarian cancer at 55 and her daughter died from an ovarian cancer at 49.
There is no information of the twin. The sister, also affected, tested positive for the mutation.
BRCA1:
c.5407-?_(*1_?)del
This large rearrangement has been described many times in the databases. As shown in Figure 2, this half




This mutation is deposited by different laboratories at least 5 times at the LOVD. The proband had triple
negative breast cancer (the type of cancer most frequently associated with BRCA1 mutations) at 47, was
tested at 49 and had a sister who died of breast cancer at 46.
BRCA2:
c.5351dup - p.(Asn1784Lysfs*3) rs80359508
We have detected this mutation 10 times and it is reported in LOVD at least 49 times (including 7 from our
laboratory) (18). The family history is relatively scarce in information, with a sister with breast cancer and the
father with prostate cancer. The daughter and one of the sons tested normal for the mutation. Considering
the origin of this mutation it may be the case that the cancer diagnosis from the Jewish side could be




Novel, not reported in the databases and we deposited at LOVD (Genomic Variant #0000206927). The
proband, tested at 67, has history of breast cancer 4 times, starting at 38, 45, 47, and 52 years of age; she
also developed ovary cancer at 60 and 64. Two relatives were tested, a niece of 38 was found to be a
non-carrier and a nephew at 41 an unaffected carrier.
BRCA2:
c.9026_9030del - p.(Tyr3009Serfs*7), rs80359741
This mutation was detected 3 times in our laboratory and at least 10 more times deposited at LOVD. This
mutation was associated to Spanish ascendancy (19).
The following variant of uncertain significance (VUS) was detected in the samples analyzed by NGS: BRCA2: c.7232A>C - p.(Lys2411Thr), rs80358950 (we deposited at LOVD Genomic
Variant #0000206714).
genetic counseling will be crucial for both paternal and maternal
relatives.
The results of this study support the guidelines recommending
genetic testing for the recurrent BRCA mutations in all AJ
breast and ovarian cancer patients (NCCN Clinical Practice in
Oncology, Version 1.2018). In addition, the value, albeit limited
to <8% more mutations, of an extended comprehensive BRCA
genotyping for high risk Ashkenazim who are negative for the
3 predominant mutations needs to be offered and discussed
with the patients at genetic counseling, regardless of the cost.
This is particularly important as having a BRCA mutation has
therapeutic implications especially in ovarian cancer cases, who
can benefit from PARP inhibitor treatment.
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